MedTrace Logo

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

NCT06407232 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-10-08

No results posted yet for this study

Summary

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Conditions

  • Cytomegalovirus Infections
  • Kidney Transplant Infection
  • Pancreas Transplant

Interventions

DRUG

Letermovir

480 mg taken orally once daily, for 84 days

Sponsors & Collaborators

Principal Investigators

  • Sandesh Parajuli, MBBS · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06407232 on ClinicalTrials.gov